Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question, ...

SGLT2 inhibitors were associated with a lower risk for major adverse cardiovascular events and heart failure hospitalization compared with DPP-4 inhibitors among patients with type 2 diabetes ...

SGLT2 inhibitors were developed to lower blood sugar in type 2 diabetes. But they do have other uses. Some of them are approved for chronic kidney disease. They also can treat heart failure.

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

SGLT2 Inhibitors Not Routinely Offered to TAVI Patients. Given the role of SGLT2 inhibitors has already been established as a pillar of guideline-directed medical therapy in heart failure, ...

When SGLT2 inhibitors were first assessed in large trials as part of an FDA requirement to prove CV safety for any new diabetes agent, most researchers hoped for just that — CV safety.

SGLT2 inhibitor users were more likely to be female (62.8% vs 54.7%), commercially insured (70.7% vs 49.2%), and to use a higher mean number of antidiabetic agents (2.7 vs 1.2 agents).

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...